Beyond GLP-1: Survodutide, Mazdutide, and the New Science of Multi-Receptor Metabolic Peptides

The New Metabolic Frontier

For decades, weight management was framed mostly as a math problem: calories in, calories out. That model is not wrong, but it is wildly incomplete. The modern science of obesity, type 2 diabetes, fatty liver disease, and cardiometabolic dysfunction shows that the body is not a simple calculator. It is more like a biochemical command center, with hormones, neural circuits, liver metabolism, pancreatic signaling, gut motility, adipose tissue, and energy expenditure all talking at once.

GLP-1 therapies changed the conversation because they showed that appetite, glucose control, and body weight can be influenced by targeting hormone receptors involved in satiety and metabolism. Semaglutide, a GLP-1 receptor agonist, helped establish the category. Tirzepatide expanded it by combining GLP-1 and GIP receptor activity. Now compounds such as survodutide and mazdutide are pushing the field into a new lane: dual activation of GLP-1 and glucagon receptors. Retatrutide goes even further as a triple agonist targeting GLP-1, GIP, and glucagon receptors. (FDA Access Data)

The big idea is simple but powerful: instead of using a single hormonal pathway, next-generation metabolic peptides are being designed to engage multiple biological levers. One lever may reduce appetite. Another may improve insulin response. Another may influence liver fat, fat oxidation, or energy expenditure. This is where the science starts to feel less like “diet medicine” and more like metabolic systems engineering.

Part 1: The Cellular Biology, Where the Real Story Begins

At the cellular level, GLP-1, GIP, and glucagon all signal through receptors that belong to the broader family of G-protein-coupled receptors. When activated, these receptors influence intracellular signaling pathways, especially cyclic AMP (cAMP), which acts as a molecular message flare inside the cell. In pancreatic beta cells, GLP-1 receptor signaling amplifies glucose-stimulated insulin secretion. That last phrase matters: glucose-stimulated. These drugs generally help insulin rise when glucose is elevated, rather than forcing insulin release regardless of blood sugar. (PMC)

GLP-1 receptor activation also affects alpha cells, the cells that produce glucagon. In many metabolic settings, GLP-1 signaling helps reduce inappropriate glucagon secretion, thereby lowering hepatic glucose production and improving blood glucose control. GLP-1 receptors are also found in brain regions involved in appetite regulation, and semaglutide’s prescribing information notes that GLP-1 is a physiological regulator of appetite and caloric intake. Semaglutide also delays gastric emptying, which can slow nutrient delivery from the stomach to the intestine and support satiety. (FDA Access Data)

GIP, or glucose-dependent insulinotropic polypeptide, is another incretin hormone. Tirzepatide uses both GLP-1 and GIP receptor activity. The Zepbound label describes tirzepatide as a GIP receptor and GLP-1 receptor agonist that selectively binds and activates both receptor types. It also notes that GIP and GLP-1 receptors are present in brain regions involved in appetite regulation, and that tirzepatide lowers body weight primarily through reduced calorie intake and appetite effects. (FDA Access Data)

Glucagon is the more misunderstood character in this metabolic drama. Traditionally, glucagon is known as the hormone that raises blood glucose by signaling the liver to release stored energy. But glucagon biology is not just “raise sugar.” Glucagon receptor activation can influence lipid metabolism, hepatic fat handling, and energy expenditure. Human research has shown that glucagon can increase energy expenditure, and dual GLP-1/glucagon approaches aim to pair GLP-1’s appetite and glucose-regulating effects with glucagon’s energy-mobilizing and liver-directed biology. (PMC)

This is the cellular logic behind survodutide and mazdutide: combine GLP-1’s satiety-and-glucose signal with glucagon’s metabolic-output signal. In plain language, GLP-1 helps turn down the “eat more” signal, while glucagon activity may help turn up selected aspects of energy utilization and liver fat metabolism. The trick is balance. Too much glucagon-like activity could theoretically push glucose upward, so successful dual agonists must be engineered to produce a useful metabolic effect without losing glycemic control. Mazdutide’s early clinical literature specifically describes its design as balancing GLP-1 and glucagon receptor activation to avoid glucagon receptor-induced hyperglycemia. (ScienceDirect)

Part 2: What Survodutide Is

Survodutide, formerly known as BI 456906, is an investigational dual agonist that activates both the GLP-1 receptor and glucagon receptor. Zealand Pharma describes it as a long-acting dual GLP-1/glucagon receptor agonist being studied for obesity and MASH, with a proposed mechanism involving reduced food intake and increased energy expenditure. Boehringer Ingelheim has also stated that survodutide remains investigational and has not been approved for use. (Zealand Pharma)

In a phase 2 obesity trial, survodutide produced dose-dependent reductions in body weight. The published trial reported that treatment with higher doses produced clinically meaningful weight loss compared with placebo, with the highest tested dose associated with approximately 14.9% body-weight reduction after 46 weeks in the planned treatment analysis. (PubMed)

Survodutide has also drawn attention in metabolic liver disease. In a phase 2 trial in MASH with fibrosis, survodutide was superior to placebo in improving MASH without worsening fibrosis. In that trial, MRI-PDFF liver-fat endpoints also showed that a substantial proportion of participants achieved at least a 30% reduction in liver fat content. (PubMed)

Most recently, Boehringer Ingelheim reported phase 3 top-line obesity results from SYNCHRONIZE-1, stating that survodutide achieved significant weight loss of up to 16.6% at 76 weeks, compared with 3.2% for placebo, while also emphasizing that the agent is still investigational. Full peer-reviewed phase 3 details were not yet available in the cited company announcement, so those results should be described as top-line data until the full dataset is published. (Boehringer Ingelheim)

Part 3: What Mazdutide Is

Mazdutide, also known as IBI362 or LY3305677, is a dual GLP-1 receptor and glucagon receptor agonist. Like survodutide, it is designed around the idea that GLP-1 receptor activation can support satiety and glucose regulation while glucagon receptor activation may contribute to energy expenditure, fat metabolism, and liver-directed metabolic effects. (ScienceDirect)

Mazdutide has advanced further commercially than survodutide in at least one market. In June 2025, Innovent announced that China’s National Medical Products Administration approved mazdutide for chronic weight management in Chinese adults with overweight or obesity. Innovent described mazdutide as the first approved dual GCG/GLP-1 receptor agonist for weight loss. (PR Newswire)

In the phase 3 GLORY-1 study published in The New England Journal of Medicine, once-weekly mazdutide in Chinese adults with obesity or overweight produced clinically relevant body-weight reductions. At week 48, mean body-weight change from baseline was reported as −11.00% in the 4 mg mazdutide group and −14.01% in the 6 mg group, compared with approximately +0.30% in the placebo group. (New England Journal of Medicine)

Mazdutide has also been studied at higher doses. A higher-dose 9 mg phase 2 study reported placebo-adjusted weight loss of −18.6% after 48 weeks, though those findings came from a company-reported phase 2 dataset rather than the GLORY-1 phase 3 approval-setting dose range. (Innovent Biologics)

The practical distinction is this: mazdutide is not just “another GLP-1.” It is part of a newer class that is trying to broaden the therapeutic lens from appetite suppression alone to a broader metabolic package: appetite, glucose, liver fat, lipid metabolism, waist circumference, and cardiometabolic risk factors. That said, its strongest regulatory and clinical evidence is currently concentrated in Chinese study populations, and global regulatory status differs by country. (PR Newswire)

Part 4: How These Compare to Semaglutide

Semaglutide is a GLP-1 receptor agonist. Its mechanism is comparatively focused: activate GLP-1 receptors, reduce appetite and calorie intake, delay gastric emptying, stimulate insulin secretion in a glucose-dependent manner, and reduce glucagon secretion. The Wegovy label states that semaglutide is a GLP-1 analog with 94% sequence homology to human GLP-1 and that it selectively binds to and activates the GLP-1 receptor. (FDA Access Data)

In the STEP 1 trial, once-weekly semaglutide 2.4 mg plus lifestyle intervention produced a mean body-weight reduction of −14.9% at 68 weeks, compared with −2.4% for placebo. This was the trial that helped cement semaglutide as a landmark obesity pharmacotherapy. (New England Journal of Medicine)

Semaglutide also has unusually strong long-term outcomes evidence for cardiovascular risk reduction. In the SELECT trial, semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without diabetes. The FDA later approved Wegovy to reduce the risk of serious heart problems in adults with cardiovascular disease and obesity or overweight. (New England Journal of Medicine)

Semaglutide has also expanded beyond weight loss and cardiovascular risk. In 2025, the FDA approved Wegovy for adults with noncirrhotic MASH with moderate-to-advanced liver fibrosis under accelerated approval, based on improvement in MASH and fibrosis, with confirmatory clinical benefit still required. (FDA Access Data)

Compared with survodutide and mazdutide, semaglutide has a narrower receptor profile but a deeper regulatory and outcomes track record in the United States. Think of semaglutide as the established single-lane metabolic highway: proven, well-studied, and clinically powerful. Survodutide and mazdutide are attempting to build a multi-lane route by adding glucagon receptor biology.

Part 5: How These Compare to Tirzepatide

Tirzepatide is not a GLP-1-only medication. It is a dual GIP/GLP-1 receptor agonist. In other words, tirzepatide activates the GIP receptor rather than the glucagon receptor. That difference matters because GIP biology is more closely tied to incretin signaling, insulin secretion, appetite regulation, and possibly adipose tissue metabolism, while glucagon receptor activation brings a more liver-and-energy-expenditure-oriented profile. (FDA Access Data)

In the SURMOUNT-1 obesity trial, tirzepatide produced substantial and sustained body-weight reductions over 72 weeks. Commonly cited results from that trial show weight loss in the range of roughly 15% to 21%, depending on dose, compared with approximately 3% for placebo. (New England Journal of Medicine)

A direct head-to-head study later found tirzepatide superior to semaglutide for reduction in body weight and waist circumference at week 72 in adults with obesity. That does not mean tirzepatide is automatically “better” for every person, because medication choice depends on indication, risk profile, tolerability, access, cardiovascular history, and clinician judgment. It does, however, show that multi-receptor incretin pharmacology can outperform GLP-1 monoagonism in terms of weight-loss magnitude in at least some trial settings. (PubMed)

Zepbound, the obesity-branded tirzepatide product, is FDA-approved for chronic weight management and is also approved for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, together with reduced-calorie diet and increased physical activity. (FDA Access Data)

Compared with survodutide and mazdutide, tirzepatide is a different kind of dual agonist. Tirzepatide says: GLP-1 plus GIP. Survodutide and mazdutide say: GLP-1 plus glucagon. One is more incretin-plus-incretin; the other is incretin-plus-energy-mobilization.

Part 6: How These Compare to Retatrutide

Retatrutide is a triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors. Eli Lilly describes retatrutide as investigational and once weekly, and it is not currently approved for routine clinical use. (Lilly)

In a phase 2 obesity trial published in The New England Journal of Medicine, retatrutide produced substantial weight reductions over 48 weeks. Lilly’s summary of the phase 2 results reported a mean weight reduction of up to 24.2% at 48 weeks in adults with obesity or overweight. The most common adverse events were gastrointestinal, dose-related, and mostly mild to moderate. (New England Journal of Medicine)

Retatrutide is scientifically important because it includes all three major receptor arms discussed here: GLP-1 for appetite and glucose regulation, GIP for incretin and appetite-related signaling, and glucagon for metabolic expenditure and liver-directed effects. If semaglutide is a single instrument and tirzepatide is a duet, retatrutide is the brass section arriving with a clipboard and a lab coat.

Compared with survodutide and mazdutide, retatrutide adds GIP receptor activation on top of GLP-1/glucagon activity. That may explain why early retatrutide weight-loss results appear especially strong, but it also means the safety, tolerability, and long-term outcomes profile must be proven in larger phase 3 programs before broad conclusions are drawn. (Lilly)

Part 7: Short-Term Effects in People

In the short term, GLP-1-based medications generally affect people through their effects on appetite, satiety, glucose handling, and digestion. Many people experience earlier fullness, smaller meal size, reduced snacking drive, and slower gastric emptying. Semaglutide and tirzepatide labels both note appetite and calorie-intake effects, glucose-dependent insulin secretion, glucagon effects, and delayed gastric emptying. (FDA Access Data)

The same mechanisms that help with satiety can also produce side effects. The most common adverse effects for GLP-1-related therapies are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, reflux-like symptoms, and reduced appetite. The Zepbound label lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease among common adverse reactions. (FDA Access Data)

For investigational agents such as retatrutide and survodutide, gastrointestinal effects have also been prominent in clinical studies. Retatrutide’s phase 2 trial reported that gastrointestinal adverse events were common, dose-related, and mostly mild to moderate. Survodutide’s obesity and MASH programs similarly show the familiar GLP-1-family tolerability theme, in which the digestive tract is often the first organ system to complain as the metabolic orchestra starts tuning up. (New England Journal of Medicine)

Short-term changes in glucose may also occur, especially in people with type 2 diabetes or insulin resistance. GLP-1 and GIP/GLP-1 therapies can improve glycemic control by increasing glucose-dependent insulin secretion and reducing glucagon secretion, but hypoglycemia risk can rise when combined with insulin or insulin secretagogues such as sulfonylureas. (FDA Access Data)

Part 8: Long-Term Effects in People

The long-term story is bigger than scale weight. Sustained treatment with GLP-1 and multi-receptor agonists can reduce fat mass, waist circumference, blood pressure, HbA1c, fasting glucose, and several cardiometabolic risk markers in clinical trials. Semaglutide and tirzepatide labels both state that weight loss is associated with greater fat-mass loss than lean-mass loss, although preservation of muscle and function remains clinically important. (FDA Access Data)

Long-term cardiovascular outcomes are strongest for semaglutide at present. SELECT showed that semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease without diabetes, which helped support the FDA cardiovascular risk-reduction indication for Wegovy. (New England Journal of Medicine)

Long-term maintenance also appears to require long-term strategy. In the STEP 1 extension, participants regained about two-thirds of their prior weight loss after semaglutide withdrawal and lifestyle intervention withdrawal. In SURMOUNT-4, withdrawing tirzepatide after initial weight loss led to substantial weight regain, while continued treatment helped maintain and extend weight loss. These findings support the modern view of obesity as a chronic, relapsing biological condition rather than a short-term “cutting phase.” (PubMed)

For survodutide, mazdutide, and retatrutide, long-term outcomes are still being built. Survodutide has promising obesity and MASH data, mazdutide has phase 3 weight-management data and China approval, and retatrutide has very strong phase 2 weight-loss signals. But long-term cardiovascular outcomes, broad real-world safety, durability, and diverse-population data remain much less mature than for semaglutide and tirzepatide. (Boehringer Ingelheim)

Part 9: Why GLP-1/Glucagon Dual Agonism Is So Interesting

The appeal of GLP-1/glucagon dual agonists is that they may address two sides of the weight-management equation: intake and expenditure. GLP-1 receptor activation can reduce appetite and caloric intake. Glucagon receptor activation may increase energy expenditure and influence hepatic lipid metabolism. This makes the GLP-1/glucagon combination especially interesting for obesity with fatty liver or broader metabolic dysfunction. (PMC)

That liver angle is not decorative. MASH and MASLD are tightly connected with obesity, insulin resistance, visceral adiposity, and cardiometabolic disease. Survodutide’s phase 2 MASH data and retatrutide’s liver-fat reduction data suggest that glucagon receptor biology may be especially relevant when the therapeutic target is not just body weight but metabolic tissue health. (PubMed)

Mazdutide’s clinical data also suggest broader metabolic effects beyond weight loss, including improvements in body weight and cardiometabolic markers in Chinese adults with overweight or obesity. However, claims should stay anchored to published trial populations and regulatory status. What happens in one population, dose range, and trial design does not automatically transfer to every patient group. (New England Journal of Medicine)

Part 10: Comparison Snapshot

Semaglutide’s strength lies in its maturity: extensive clinical data, cardiovascular outcomes evidence, and multiple approved indications. Tirzepatide’s strength lies in its magnitude of weight loss and dual incretin pharmacology. Survodutide and mazdutide are compelling because they add glucagon receptor activation, which may matter for energy expenditure, liver fat, and broader metabolic remodeling. Retatrutide is the most expansive mechanistically, but it remains investigational and needs phase 3 confirmation. (FDA Access Data)

Conclusion: From Appetite Control to Metabolic Architecture

The next chapter of metabolic medicine is not simply “stronger GLP-1s.” It is a shift toward multi-receptor metabolic design.

Semaglutide showed how powerful GLP-1 receptor activation could be. Tirzepatide showed that adding GIP could increase the efficacy of weight loss. Survodutide and mazdutide are exploring a different direction: pairing GLP-1 with glucagon to influence appetite, glucose handling, energy expenditure, and liver metabolism. Retatrutide combines all three major receptor pathways and may represent the most ambitious version of this strategy, though it remains investigational. (New England Journal of Medicine)

For patients and clinicians, the lesson is not that one molecule is universally “best.” The lesson is that obesity and metabolic disease are biological systems, and different receptor combinations may serve different clinical goals: weight reduction, glucose control, cardiovascular risk reduction, sleep apnea improvement, liver-fat reduction, or long-term maintenance.

For science communicators and brands, the opportunity is to educate responsibly. These molecules are fascinating, but they are not wellness shortcuts or casual-use products. They are potent biological tools that belong in evidence-based, regulated, medically supervised contexts. The future is exciting, but it still wears a lab coat.

Key References Used

1. FDA prescribing information for Wegovy, including GLP-1 mechanism, appetite regulation, insulin/glucagon effects, gastric emptying, and weight-loss trial data. (FDA Access Data)

2. FDA prescribing information for Zepbound, including GIP/GLP-1 mechanism, appetite regulation, insulin sensitivity, gastric emptying, and OSA indication. (FDA Access Data)

3. STEP 1 semaglutide obesity trial and SELECT cardiovascular outcomes trial. (New England Journal of Medicine)

4. SURMOUNT-1 tirzepatide obesity trial and SURMOUNT-4 withdrawal/maintenance data. (New England Journal of Medicine)

5. Survodutide obesity and MASH trial literature, plus current investigational status. (PubMed)

6. Mazdutide GLORY-1 phase 3 data and China approval announcement. (New England Journal of Medicine)

7. Retatrutide phase 2 obesity data and investigational status. (New England Journal of Medicine)